Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT05322473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Study identification
- NCT ID
- NCT05322473
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 234 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 24, 2022
- Primary completion
- May 8, 2023
- Completion
- Aug 29, 2023
- Last update posted
- May 2, 2024
2022 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site | Fountain Valley | California | 92708 | — |
| Clinical Site | Los Angeles | California | 90056 | — |
| Clinical Site | Miami | Florida | 33136 | — |
| Clinical Site | Ormond Beach | Florida | 32127 | — |
| Clinical Site | St. Petersburg | Florida | 33709 | — |
| Clinical Site | Tampa | Florida | 33613 | — |
| Clinical Site | Indianapolis | Indiana | 46250 | — |
| Clinical Site | Beverly | Massachusetts | 01915 | — |
| Clinical Site | Boston | Massachusetts | 02215 | — |
| Clinical Site | Omaha | Nebraska | 68144 | — |
| Clinical Site | New York | New York | 10003 | — |
| Clinical Site | Philadelphia | Pennsylvania | 19103 | — |
| Clinical Site | Charleston | South Carolina | 29425 | — |
| Clinical Site | Nashville | Tennessee | 37215 | — |
| Clinical Site | Bellaire | Texas | 77401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05322473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05322473 live on ClinicalTrials.gov.